Direct Answer: Many products marketed as "stem cell therapy" — often derived from amniotic fluid, umbilical cord tissue, or other donor (allogeneic) sources — contain few or no living, functional stem cells by the time they reach a patient. Autologous therapies, like bone marrow aspirate concentrate (BMAC), use a patient's own cells collected and processed at the point of care, which is a fundamentally different category of treatment. Patients considering "stem cell" treatment should understand this distinction before choosing a provider.
What This Means for You
"Stem cell therapy" has become a marketing term almost as much as a medical one. Some clinics sell injectable products sourced from donated amniotic or birth tissue and market them as stem cell treatments, even though independent lab analyses of many of these products have found minimal to no viable stem cells present. This isn't necessarily fraud in every case — regulation and labeling in this space has lagged behind the marketing — but it does mean patients can pay for a "stem cell" treatment that isn't delivering what the name implies.
Autologous treatments are different: they use a patient's own tissue (bone marrow or adipose/fat tissue), collected and processed during the same visit, so the cellular content — while it varies by patient — comes directly from that patient's own biology rather than a commercial product.
Dr. Tortland's Perspective
This is a distinction I think every patient researching regenerative medicine deserves to understand clearly, and it's one of the reasons I focus specifically on autologous, point-of-care treatments like BMAC. If a clinic can't explain where the cellular material in their product actually comes from — or can't show you regulatory documentation — that's worth pausing on. I'd rather a patient walk in informed and ask hard questions than be sold on a name alone.